Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Hovione partners with Dragonfly Technologies to offer micellar chemistry technology to customers as a sustainable alternative to conventional chemical processes

Press Release / Mar 07, 2024
Article
View

Sunriser® DPI

High Performance, High-Dose Capsule DPI.

Page
Read more

Particle Engineering for Inhalation and Nasal

Hovione is a global expert and recognized leader in particle engineering, an essential technology when developing inhalation drug products.

Page
Read more